CA2243302C - Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain - Google Patents

Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain Download PDF

Info

Publication number
CA2243302C
CA2243302C CA002243302A CA2243302A CA2243302C CA 2243302 C CA2243302 C CA 2243302C CA 002243302 A CA002243302 A CA 002243302A CA 2243302 A CA2243302 A CA 2243302A CA 2243302 C CA2243302 C CA 2243302C
Authority
CA
Canada
Prior art keywords
monoclonal antibody
human vegf
flt
vegf receptor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002243302A
Other languages
English (en)
Other versions
CA2243302A1 (fr
Inventor
Kenya Shitara
Mikito Ito
Nobuo Hanai
Masabumi Shibuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority claimed from PCT/JP1997/004259 external-priority patent/WO1998022616A1/fr
Publication of CA2243302A1 publication Critical patent/CA2243302A1/fr
Application granted granted Critical
Publication of CA2243302C publication Critical patent/CA2243302C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps monoclonal qui réagit immunologiquement avec un récepteur F1t-1 VEGF humain, des cellules comportant le récepteur F1t-1 VEGF humain exprimé et analogues. Ledit anticorps monoclonal présente une activité inhibitrice à l'encontre de la liaison d'un VEGF humain avec un récepteur F1t-1 VEGF. La présente invention concerne également l'utilisation de l'anticorps monoclonal pour le diagnostic et le traitement de maladies dans lesquelles la condition pathologique progresse par vascularisation anormale à savoir la propagation et les métastases des tumeurs solides, l'arthrite dans les rhumatismes articulaires chroniques, la rétinopathie diabétique, la rétinopathie de prématurité et le psoriasis.
CA002243302A 1996-11-21 1997-11-21 Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain Expired - Lifetime CA2243302C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31110996 1996-11-21
JP8-311109 1996-11-21
PCT/JP1997/004259 WO1998022616A1 (fr) 1996-11-21 1997-11-21 Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain

Publications (2)

Publication Number Publication Date
CA2243302A1 CA2243302A1 (fr) 1998-05-28
CA2243302C true CA2243302C (fr) 2007-07-03

Family

ID=38279490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002243302A Expired - Lifetime CA2243302C (fr) 1996-11-21 1997-11-21 Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain

Country Status (1)

Country Link
CA (1) CA2243302C (fr)

Also Published As

Publication number Publication date
CA2243302A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
EP0882799B1 (fr) Anticorps monoclonal dirige contre le recepteur flt-1 du vegf humain
US7615215B2 (en) Anti-human VEGF receptor Flt-1 monoclonal antibody
EP1086705A1 (fr) Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
WO1999040118A1 (fr) Anticorps diriges contre le recepteur kdr humain du vegf
CN113999303B (zh) 用于体外诊断的新型冠状病毒核衣壳蛋白抗体
WO2014169494A1 (fr) Anticorps monoclonal reconnaissant spécifiquement des protéines mutantes egfr, et son procédé de préparation et son utilisation
AU767731B2 (en) Gene recombinant antibodies
US20030175271A1 (en) VEGF activity inhibitor
US11906520B2 (en) Composition and methods for detecting cancer
CA2243302C (fr) Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain
JP2001046066A (ja) 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
EP1199565B1 (fr) Moyens de diagnostic et de traitement de maladies utilisant des macrocytes/macrophages
EP0905235A2 (fr) Facteur de croissance pour des cellules des muscles vasculaires lisses
JP4493882B2 (ja) 抗原およびこの抗原を識別するモノクローナル抗体
JPH0759588A (ja) 増殖因子レセプターに対するモノクローナル抗体の製造方法及び抗ｃ−ｅｒｂＢ−２モノクローナル抗体
EP1160572A1 (fr) Moyen de diagnostic et de traitement de la leucemie
AU2004200700B2 (en) Gene Recombinant Antibody
CN101193915A (zh) 单克隆抗体及其用于检测宫颈疾病的方法
JP3472664B2 (ja) 抗繊維芽細胞増殖因子５モノクローナル抗体
CN101492504A (zh) 抗HnRNP B1抗原的单克隆抗体的制备及其应用
WO1991012333A1 (fr) Anticorps monoclonal antiprocollagenase et essai de depistage de procollagenase au moyen de cet anticorps
KR20110095541A (ko) 무등 단백질에 대한 단일클론 항체 및 그 응용

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171121